Program
nelitolimod
Also written as “SD-101”, “SD-101 Dermal Cream (6%)” and “SD-101-6.0 cream”.
Its studies are mostly in Epidermolysis Bullosa · Carcinoma, Hepatocellular · Uveal Melanoma · Melanoma · Lymphoma, B-Cell, led by 5 companies.
Drug pageNelitolimod: every studyMany companies study it; this page follows only the 14 they lead. All 25 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceuticalits history only | 40 open or running | phase 3since Feb 13, 2015 | Dec 12, 2013 | none ahead |
| Sanofiits history only | 40 open or running | phase 2since Oct 13, 2014 | Jan 11, 2008 | none ahead |
| TriSalus Life Sciencesits history only | 31 open or running | phase 2since Jan 21, 2022 | Jun 2, 2021 | Sep 2027phase 1 · NCT05607953 |
| Paradigm Therapeuticsits history only | 22 open or running | phase 3since Mar 4, 2026 | Mar 4, 2026 | May 17, 2027phase 3 · NCT07482787 |
| Merckits history only | 10 open or running | phase 1since Apr 4, 2016 | Apr 4, 2016 | none ahead |
Also a collaborator on its studies: Synteract and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 11, 2008First study: phase 1 study in HealthyNew to SanofiSanofi · NCT00599001 · 26 enrolled · United States
- Jan 14, 2009Phase 1 study in Hepatitis C, ChronicSanofi · NCT00823862 · 34 enrolled · Poland
- Dec 12, 2013BioMarin Pharmaceutical’s first study: phase 2 study in Epidermolysis BullosaNew to BioMarin PharmaceuticalBioMarin Pharmaceutical · NCT02014376 · 48 enrolled · United States
- Mar 12, 2014Phase 2 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02090283 · 42 enrolled · United States
- Oct 13, 2014Phase 2 study in Lymphoma, B-CellSanofi · NCT02266147 · 29 enrolled · United States
- Feb 13, 2015Phase 3 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02384460 · 169 enrolled · United States, Australia, Austria and more
- Jul 28, 2015Phase 3 study in Epidermolysis BullosaBioMarin Pharmaceutical · NCT02670330 · 152 enrolled · United States, Australia, Austria and more
- Jul 30, 2015Phase 2 study in MelanomaSanofi · NCT02521870 · 241 enrolled · United States, Australia, Germany and more
- Apr 4, 2016Merck’s first study: phase 1 study in NeoplasmsNew to MerckMerck · NCT02731742 · 14 enrolled
- Jun 2, 2021TriSalus Life Sciences’ first study: phase 1 study in Uveal MelanomaNew to TriSalus Life SciencesTriSalus Life Sciences · NCT04935229 · 67 enrolled · United States
- Jan 21, 2022Phase 2 study in Carcinoma, HepatocellularTriSalus Life Sciences · NCT05220722 · 23 enrolled · United States
- Oct 19, 2022Phase 1 study in Locally Advanced Pancreatic AdenocarcinomaTriSalus Life Sciences · NCT05607953 · 60 enrolled · United States
- Aug 11, 2024Named nelitolimodINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SD-101
- Mar 4, 2026Paradigm Therapeutics’ first studies: 2 phase 3 studies in Epidermolysis BullosaNew to Paradigm TherapeuticsParadigm Therapeutics · NCT07482813, NCT07482787
Ahead
- May 17, 2027Primary completion: phase 3 study in Epidermolysis BullosaParadigm Therapeutics · NCT07482787
- Sep 2027Primary completion: phase 1 study in Locally Advanced Pancreatic AdenocarcinomaTriSalus Life Sciences · NCT05607953
- Sep 19, 2027Primary completion: phase 3 study in Epidermolysis BullosaParadigm Therapeutics · NCT07482813
TargetBeta
“A class C CpG-oligodeoxynucleotide (ODN) agonist of toll-like receptor 9 (TLR9), with immunostimulatory, immunoadjuvant and antineoplastic activities”NCIt, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07482813Epidermolysis Bullosa | 3 | Not yet recruiting | Paradigm Therapeutics | Sep 19, 2027 | 80 |
| NCT07482787Epidermolysis Bullosa · United States | 3 | Recruiting | Paradigm Therapeutics | May 17, 2027 | 80 |
| NCT05607953Locally Advanced Pancreatic Adenocarcinoma · United States | 1 | Active, not recruiting | TriSalus Life Sciences | Sep 2027 | 60 |
| NCT05220722Carcinoma, Hepatocellular · United States | 2 | Terminated | TriSalus Life Sciences | Jul 31, 2024 | 23 |
| NCT04935229Uveal Melanoma · United States | 1 | Terminated | TriSalus Life Sciences | Jul 17, 2024 | 67 |
| NCT02731742Neoplasms | 1 | Terminated | Merck | Jan 8, 2018 | 14 |
| NCT02521870Melanoma · United States, Australia, Germany and more | 2 | Terminated | Sanofi | Apr 2020 | 241 |
| NCT02670330Epidermolysis Bullosa · United States, Australia, Austria and more | 3 | Terminated | BioMarin Pharmaceutical | Sep 3, 2018 | 152 |
| NCT02384460Epidermolysis Bullosa · United States, Australia, Austria and more | 3 | Completed | BioMarin Pharmaceutical | Jul 5, 2017 | 169 |
| NCT02266147Lymphoma, B-Cell · United States | 2 | Terminated | Sanofi | Apr 2017 | 29 |
| NCT02090283Epidermolysis Bullosa · United States | 2 | Terminated | BioMarin Pharmaceutical | Sep 14, 2018 | 42 |
| NCT02014376Epidermolysis Bullosa · United States | 2 | Completed | BioMarin Pharmaceutical | Jun 24, 2014 | 48 |
| NCT00823862Hepatitis C, Chronic · Poland | 1 | Completed | Sanofi | Dec 2009 | 34 |
| NCT00599001Healthy · United States | 1 | Completed | Sanofi | Mar 2008 | 26 |
How it is read
Names in the registry
- “SD-101”, 7 entries
- “SD-101 Dermal Cream (6%)”, 3 entries
- “SD-101-6.0 cream”, 2 entries
- “SD-101(1)”, 1 entry
- “SD-101(2)”, 1 entry
Conditions, from the studies’ own filings
- Epidermolysis Bullosa, 6 studies
- Carcinoma, Hepatocellular, 1 study
- Uveal Melanoma, 1 study
- Melanoma, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.